{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:37:55Z","timestamp":1790933875937,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T00:00:00Z","timestamp":1363392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s13277-013-0739-6","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T11:04:10Z","timestamp":1363345450000},"page":"1337-1347","source":"Crossref","is-referenced-by-count":50,"title":["PCA3 in the detection and management of early prostate cancer"],"prefix":"10.1007","volume":"34","author":[{"given":"Xavier","family":"Filella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Foj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Aug\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimiro","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,16]]},"reference":[{"key":"739_CR1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","volume":"279","author":"WJ Catalona","year":"1998","unstructured":"Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542\u20137.","journal-title":"JAMA"},{"key":"739_CR2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","volume":"48","author":"AW Roddam","year":"2005","unstructured":"Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2\u201310\u00a0ng\/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386\u201399.","journal-title":"Eur Urol"},{"key":"739_CR3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","volume":"94","author":"R Etzioni","year":"2002","unstructured":"Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Nat Cancer Inst. 2002;94:981\u201390.","journal-title":"J Nat Cancer Inst"},{"key":"739_CR4","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","volume":"291","author":"JE Johansson","year":"2004","unstructured":"Johansson JE, Andr\u00e9n O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713\u20139.","journal-title":"JAMA"},{"key":"739_CR5","doi-asserted-by":"crossref","unstructured":"Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, et al. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2012 Aug 6","DOI":"10.1016\/j.critrevonc.2011.10.003"},{"key":"739_CR6","doi-asserted-by":"crossref","unstructured":"Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2012; doi: 10.1111\/j.1464-410X.2012.11329.x .","DOI":"10.1111\/j.1464-410X.2012.11329.x"},{"key":"739_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/cclm-2012-0410","volume":"15","author":"X Filella","year":"2012","unstructured":"Filella X, Gim\u00e9nez N. Evaluation of [\u22122] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med. 2012;15:1\u201311.","journal-title":"Clin Chem Lab Med"},{"key":"739_CR8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-10-1003","volume":"20","author":"AJ Vickers","year":"2011","unstructured":"Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15\u00a0years without screening. Cancer Epidemiol Biomarkers Prev. 2011;20:255\u201361.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"739_CR9","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1158\/1078-0432.CCR-10-0122","volume":"16","author":"AJ Vickers","year":"2010","unstructured":"Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res. 2010;16:3232\u20139.","journal-title":"Clin Cancer Res"},{"key":"739_CR10","first-page":"5975","volume":"59","author":"MJ Bussemakers","year":"1999","unstructured":"Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975\u20139.","journal-title":"Cancer Res"},{"key":"739_CR11","first-page":"2695","volume":"62","author":"JB Kok de","year":"2002","unstructured":"de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695\u20138.","journal-title":"Cancer Res"},{"key":"739_CR12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1471-2407-12-507","volume":"12","author":"LB Ferreira","year":"2012","unstructured":"Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012;12:507. doi: 10.1186\/1471-2407-12-507 .","journal-title":"BMC Cancer"},{"key":"739_CR13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","volume":"52","author":"J Groskopf","year":"2006","unstructured":"Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089\u201395.","journal-title":"Clin Chem"},{"key":"739_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","volume":"44","author":"D Hessels","year":"2003","unstructured":"Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8\u201315.","journal-title":"Eur Urol"},{"key":"739_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.urology.2004.03.052","volume":"64","author":"Y Fradet","year":"2004","unstructured":"Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64:311\u20135.","journal-title":"Urology"},{"key":"739_CR16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2004.06.004","volume":"46","author":"M Tinzl","year":"2004","unstructured":"Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine\u2014a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182\u20136.","journal-title":"Eur Urol"},{"key":"739_CR17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-06-2679","volume":"13","author":"MP Gils van","year":"2007","unstructured":"van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination: a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:939\u201343.","journal-title":"Clin Cancer Res"},{"key":"739_CR18","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.juro.2009.01.110","volume":"181","author":"B Ouyang","year":"2009","unstructured":"Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol. 2009;181:2508\u201313.","journal-title":"J Urol"},{"key":"739_CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13547500902807306","volume":"14","author":"E Mearini","year":"2009","unstructured":"Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers. 2009;14:235\u201343.","journal-title":"Biomarkers"},{"key":"739_CR20","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/pros.21211","volume":"70","author":"M Rigau","year":"2010","unstructured":"Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate. 2010;70:1760\u20137.","journal-title":"Prostate"},{"key":"739_CR21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/pros.21390","volume":"71","author":"M Rigau","year":"2011","unstructured":"Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llaurad\u00f3 M, et al. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate. 2011;71:1736\u201345.","journal-title":"Prostate"},{"key":"739_CR22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yexmp.2010.10.009","volume":"90","author":"M Shen","year":"2011","unstructured":"Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol. 2011;90:97\u2013100.","journal-title":"Exp Mol Pathol"},{"key":"739_CR23","doi-asserted-by":"crossref","unstructured":"Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011, May 19.","DOI":"10.1016\/j.urolonc.2011.04.001"},{"key":"739_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2007.11.003","volume":"389","author":"LJ Sokoll","year":"2008","unstructured":"Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008;389:1\u20136.","journal-title":"Clin Chim Acta"},{"key":"739_CR25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.acuro.2010.02.019","volume":"34","author":"J Ruiz-Arag\u00f3n","year":"2010","unstructured":"Ruiz-Arag\u00f3n J, M\u00e1rquez-Pel\u00e1ez S. Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis. Actas Urol Esp. 2010;34:346\u201355.","journal-title":"Actas Urol Esp"},{"key":"739_CR26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61\u201371.","journal-title":"Eur Urol"},{"key":"739_CR27","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","volume":"179","author":"IL Deras","year":"2008","unstructured":"Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587\u201392.","journal-title":"J Urol"},{"key":"739_CR28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","volume":"54","author":"A Haese","year":"2008","unstructured":"Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081\u20138.","journal-title":"Eur Urol"},{"key":"739_CR29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","volume":"179","author":"H Nakanishi","year":"2008","unstructured":"Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804\u20139.","journal-title":"J Urol"},{"key":"739_CR30","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.juro.2008.07.060","volume":"180","author":"EJ Whitman","year":"2008","unstructured":"Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975\u20138.","journal-title":"J Urol"},{"key":"739_CR31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/pros.20781","volume":"68","author":"MP Gils van","year":"2008","unstructured":"van Gils MP, Hessels D. Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 2008;68:1215\u201322.","journal-title":"Prostate"},{"key":"739_CR32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.urology.2009.03.046","volume":"75","author":"V Vlaeminck-Guillem","year":"2010","unstructured":"Vlaeminck-Guillem V, Ruffion A, Andr\u00e9 J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010;75:447\u201353.","journal-title":"Urology"},{"key":"739_CR33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jomh.2011.03.006","volume":"8","author":"X Durand","year":"2011","unstructured":"Durand X, Xylinas E, Ploussard G, de la Taille A. What information can a PCA3 urine test provide in the diagnosis and treatment of prostate cancer. Journal of Men\u2019s Health. 2011;8:164\u20139.","journal-title":"Journal of Men\u2019s Health"},{"key":"739_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOU.0b013e328344939c","volume":"21","author":"MJ Roobol","year":"2011","unstructured":"Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol. 2011;21:225\u20139.","journal-title":"Curr Opin Urol"},{"key":"739_CR35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2010.06.039","volume":"58","author":"MJ Roobol","year":"2010","unstructured":"Roobol MJ, Schr\u00f6der FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010;58:475\u201381.","journal-title":"Eur Urol"},{"key":"739_CR36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2010.09.030","volume":"58","author":"MJ Roobol","year":"2010","unstructured":"Roobol MJ, Schr\u00f6der FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (\u2265 100). Eur Urol. 2010;58:893\u20139.","journal-title":"Eur Urol"},{"key":"739_CR37","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","volume":"184","author":"SM Aubin","year":"2010","unstructured":"Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184:1947\u201352.","journal-title":"J Urol"},{"key":"739_CR38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.juro.2011.01.075","volume":"185","author":"A Taille de la","year":"2011","unstructured":"de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185:2119\u201325.","journal-title":"J Urol"},{"key":"739_CR39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.acuroe.2012.01.002","volume":"35","author":"J Rubio-Briones","year":"2011","unstructured":"Rubio-Briones J, Fern\u00e1ndez-Serra A, Ram\u00edrez M, Rubio L, Collado A, Casanova J, et al. Resultados del uso expandido del PCA3 score en una poblaci\u00f3n espa\u00f1ola con sospecha de c\u00e1ncer de pr\u00f3stata. Actas Urol Esp. 2011;35:589\u201396.","journal-title":"Actas Urol Esp"},{"key":"739_CR40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1464-410X.2010.09286.x","volume":"106","author":"G Ploussard","year":"2010","unstructured":"Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies. BJU Int. 2010;106:1143\u20137.","journal-title":"BJU Int"},{"key":"739_CR41","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1464-410X.2011.10584.x","volume":"109","author":"M Auprich","year":"2012","unstructured":"Auprich M, Augustin H, Bud\u00e4us L, Kluth L, Mannweiler S, Shariat SF, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int. 2012;109:1627\u201335.","journal-title":"BJU Int"},{"key":"739_CR42","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.juro.2012.07.023","volume":"188","author":"ED Crawford","year":"2012","unstructured":"Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726\u201331.","journal-title":"J Urol"},{"key":"739_CR43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pros.22561","volume":"73","author":"S Perdon\u00e0","year":"2013","unstructured":"Perdon\u00e0 S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate. 2013;73:227\u201335.","journal-title":"Prostate"},{"key":"739_CR44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.cca.2012.04.017","volume":"413","author":"M Ferro","year":"2012","unstructured":"Ferro M, Bruzzese D, Perdon\u00e0 S, Mazzarella C, Marino A, Sorrentino A, et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta. 2012;413:1274\u20138.","journal-title":"Clin Chim Acta"},{"key":"739_CR45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1373\/clinchem.2012.195560","volume":"59","author":"C Stephan","year":"2013","unstructured":"Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [\u22122]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem. 2013;59:280\u20138.","journal-title":"Clin Chem"},{"key":"739_CR46","doi-asserted-by":"crossref","unstructured":"Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012 Nov 15. doi: 10.1016.","DOI":"10.1016\/j.juro.2012.02.2272"},{"key":"739_CR47","doi-asserted-by":"crossref","unstructured":"Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3:94ra72.","DOI":"10.1126\/scitranslmed.3001970"},{"key":"739_CR48","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.juro.2008.06.038","volume":"180","author":"DP Ankerst","year":"2008","unstructured":"Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008;180:1303\u20138.","journal-title":"J Urol"},{"key":"739_CR49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2009.03.029","volume":"56","author":"FK Chun","year":"2009","unstructured":"Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009;56:659\u201367.","journal-title":"Eur Urol"},{"key":"739_CR50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","volume":"60","author":"M Auprich","year":"2011","unstructured":"Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011;60:1045\u201354.","journal-title":"Eur Urol"},{"key":"739_CR51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2010.09.036","volume":"59","author":"S Perdon\u00e0","year":"2011","unstructured":"Perdon\u00e0 S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, et al. Prostate cancer detection in the \u201cgrey area\u201d of prostate-specific antigen below 10\u00a0ng\/ml: head-to-head comparison of the updated PCPT calculator and Chun\u2019s nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol. 2011;59:81\u20137.","journal-title":"Eur Urol"},{"key":"739_CR52","doi-asserted-by":"crossref","unstructured":"Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2012 Jul 20.","DOI":"10.1016\/j.eururo.2012.07.030"},{"key":"739_CR53","first-page":"459","volume":"18","author":"CF Ng","year":"2012","unstructured":"Ng CF, Yeung R, Chiu PK, Lam NY, Chow J, Chan B. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J. 2012;18:459\u201365.","journal-title":"Hong Kong Med J"},{"key":"739_CR54","doi-asserted-by":"crossref","unstructured":"Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama SI, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013 Jan 18. doi: 10.1111\/j.1464-410X.2012.11683.x","DOI":"10.1111\/j.1464-410X.2012.11683.x"},{"key":"739_CR55","first-page":"553","volume":"33","author":"M Salagierski","year":"2013","unstructured":"Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res. 2013;33:553\u20137.","journal-title":"Anticancer Res"},{"key":"739_CR56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2010.10.024","volume":"59","author":"M Auprich","year":"2011","unstructured":"Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011;59:96\u2013105.","journal-title":"Eur Urol"},{"key":"739_CR57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2010.11.044","volume":"59","author":"G Ploussard","year":"2011","unstructured":"Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011;59:422\u20139.","journal-title":"Eur Urol"},{"key":"739_CR58","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.2011.10377.x","volume":"109","author":"H Poppel van","year":"2012","unstructured":"van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between Prostate Cancer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012;109:360\u20136.","journal-title":"BJU Int"},{"key":"739_CR59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1464-410X.2011.10682.x","volume":"110","author":"X Durand","year":"2012","unstructured":"Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 2012;110:43\u20139.","journal-title":"BJU Int"},{"key":"739_CR60","doi-asserted-by":"crossref","unstructured":"Augustin H, Mayrhofer K, Pummer K, Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate. 2012; doi: 10.1002\/pros.22558 .","DOI":"10.1002\/pros.22558"},{"key":"739_CR61","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00345-010-0623-6","volume":"29","author":"MA Liss","year":"2011","unstructured":"Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. 2011;29:683\u20138.","journal-title":"World J Urol"},{"key":"739_CR62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pros.21032","volume":"70","author":"D Hessels","year":"2010","unstructured":"Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70:10\u20136.","journal-title":"Prostate"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-0739-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-013-0739-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-0739-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T14:26:55Z","timestamp":1644589615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-013-0739-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,16]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s13277-013-0739-6","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,16]]}}}